Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans

D. A. Martins, N. Mazibuko, F. Zelaya, S. Vasilakopoulou, J. Loveridge, A. Oates, S. Maltezos, M. Mehta, S. Wastling, M. Howard, G. McAlonan, D. Murphy, S. C. R. Williams, A. Fotopoulou, U. Schuschnig and Y. Paloyelis ()
Additional contact information
D. A. Martins: King’s College London
N. Mazibuko: King’s College London
F. Zelaya: King’s College London
S. Vasilakopoulou: King’s College London
J. Loveridge: King’s College London
A. Oates: South London and Maudsley NHS Foundation Trust
S. Maltezos: South London and Maudsley NHS Foundation Trust
M. Mehta: King’s College London
S. Wastling: King’s College London
M. Howard: King’s College London
G. McAlonan: King’s College London
D. Murphy: King’s College London
S. C. R. Williams: King’s College London
A. Fotopoulou: University College London
U. Schuschnig: PARI GmbH
Y. Paloyelis: King’s College London

Nature Communications, 2020, vol. 11, issue 1, 1-16

Abstract: Abstract Could nose-to-brain pathways mediate the effects of peptides such as oxytocin (OT) on brain physiology when delivered intranasally? We address this question by contrasting two methods of intranasal administration (a standard nasal spray, and a nebulizer expected to improve OT deposition in nasal areas putatively involved in direct nose-to-brain transport) to intravenous administration in terms of effects on regional cerebral blood flow during two hours post-dosing. We demonstrate that OT-induced decreases in amygdala perfusion, a key hub of the OT central circuitry, are explained entirely by OT increases in systemic circulation following both intranasal and intravenous OT administration. Yet we also provide robust evidence confirming the validity of the intranasal route to target specific brain regions. Our work has important translational implications and demonstrates the need to carefully consider the method of administration in our efforts to engage specific central oxytocinergic targets for the treatment of neuropsychiatric disorders.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-14845-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14845-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-14845-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().